Navigation Links
Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
Date:6/1/2011

GENEVA, June 1, 2011 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company with technologies for the rapid development and engineering of high yield and stable mammalian cell lines for therapeutic protein manufacturing of recombinant drugs announced today representatives from the Company will be participating in the 2011 BIO International Convention's One-on-One Partnering Meetings being held Jun 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.

Selexis has interactive collaborations, partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. Selexis' SURE technology platform allows for faster and more reliable cell line development with higher expression levels which can be applied to a wide range of areas such as bio-manufacturing, drug discovery, diagnostics and therapeutics.

Representatives available to discuss Selexis' capabilities include: Dr. Igor Fisch, CEO; Andrew Sandford, VP Business Development and Licensing; Dr. Armelle Gaussin, Chief Technology Officer; and Dr. Denise Huber, Director of Business Development. Companies or individuals attending BIO 2011 can schedule meetings with Selexis by visiting (registration required): oneononepartnering.bio.org/BusinessForum2011/Login.aspx.

Selexis Partnering Schedule:

Monday, June 27 Business Forum  -  12:00 PM - 5:00 PM

Tuesday, June 28 Business Forum  -  7:00 AM – 6:00 PM

Wednesday, June 29 Business Forum  -  7:00 AM – 6:00 PM

Thursday, June 30 Business Forum  -  7:00 AM – 6:00 PM

For companies or individuals not participating in partnering meetings, Selexis will be exhibiting in booth number #1906 located in Hall A – Discovery Zone (e.mybio.zerista.com/exhibitor/member/17326). For the exhibit hall schedule, visit: e.mybio.zerista.com/event/print

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SUREvariant Screening™ and the proprietary Selexis SURE CHO-M Cell Line™.

For more information visit www.selexis.com

Contact:
Robert Meister
(602) 953-1716
robert.meister@selexis.com


'/>"/>
SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
2. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
3. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
4. Selexis Launches Biosimilar Cell Line Development Program
5. Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development
6. Local Partnership Addresses Lagging Scores and Interest in Science and Math Among Students
7. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
8. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
9. Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research
10. Aperio Partners with Definiens to Market Definiens Tissue Studio for Advanced Image Analysis
11. John McKearn, Ph.D., Promoted to Managing Director of RiverVest Venture Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... CA (PRWEB) , ... May 19, 2017 , ... ... annual meeting and educational conference of the American Association of Bioanalysts (AAB) and ... Galleria Hotel in Houston. The conference reinforces AAB’s commitment to excellence in clinical ...
(Date:5/18/2017)... (PRWEB) , ... May 18, 2017 , ... ... procedure on April 28, 2017 at the Prince Of Wales Private Hospital. The ... disc at level C6-C7. The patient failed conservative treatments prior to undergoing surgery. ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... expertise, and further enhances its scientific power by providing investigators access to ... has agreed to join the scientific advisory board. “We are committed to ...
(Date:5/18/2017)... ... 17, 2017 , ... G-CON Manufacturing, Inc., the leader in ... Jornitz, was recognized as a Top 10 Industry Influencer on The Medicine Maker’s ... bettering the pharma industry and bringing life-changing medicines to market” across four categories. ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):